Key result
Natriuretic peptide assessment advances HF management by aiding diagnosis, prognosis, treatment, and community prevention.
Why the study?
What are the established and potential new roles for natriuretic peptide assessment in the community for heart failure management?
What are the established and potential new roles for natriuretic peptide assessment in the community for heart failure management?
Natriuretic peptide assessment serves as a reliable biomarker to aid in the diagnosis, prognosis, and management of heart failure in the community.
Supports community HF management; leaves open optimal thresholds and prospective validation.
Natriuretic peptide assessment has represented a significant advance in the management of heart failure. In a syndrome in which clinical symptoms and signs can be either nonspecific or absent, the presence of a reliable biomarker to aid diagnosis, assess prognosis, and potentially guide treatment and aid in prevention of this syndrome has represented a significant advance. The following review will outline established and potential new roles for natriuretic peptide assessment in the community.
No takes yet. Share an insight, caveat, or question.
McDonald et al. (2008) conducted a review in Heart failure. Natriuretic peptide assessment was evaluated. Natriuretic peptide assessment represents a significant advance in the management of heart failure, aiding in diagnosis, prognosis, treatment guidance, and prevention in the community.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: